IBA Agrees To a Contract with CGN Medical Tech For Installation of Proteus PLUS System By CIOTechOutlook Team

IBA Agrees To a Contract with CGN Medical Tech For Installation of Proteus PLUS System

CIOTechOutlook Team | Tuesday, 13 June 2023, 06:28 IST

The West China International Cancer Treatment Centre in Chengdu, Sichuan Province, will receive one gantry treatment room equipped with IBA's Proteus®PLUS1 proton therapy system. IBA, the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announced it has signed an equipment contract with its partner CGN Medical Technology.

The only supplier of proton therapy equipment to Chengdu's West China International Cancer Treatment Centre is CGNMT. After IBA and CGNNT agreed to a strategic licencing deal in 2020, IBA gives CGNMT the essential parts of the Proteus®PLUS system, which CGNMT will deploy at the hospital.

Olivier Legrain, Chief Executive Officer of IBA, commented: “This project is the ninth Proteus®PLUS system to be installed in China and the second order received from CGNMT since the beginning of our successful collaboration. We were happy to meet the management team of CGNMT in person for the first time since the pandemic and the signature of our agreement. We have been impressed with the progress that has been made so far by our partner and look forward to continuing our relationship with them to ensure the future success and expansion of proton therapy in the Chinese market.”

HU Dongming, Chairman of CGN Nuclear Technology Development Co., Ltd., added: “We were happy to welcome Mr. Legrain and his team to CGN in Shenzhen and celebrate the fantastic progress we have made in the delivery of this innovative technology to the Chinese market. We are pleased and honored to be working with the West China International Cancer Treatment Center which demonstrates the potential of our collaboration for the benefit of cancer patients in China. We look forward to strengthening our relationship with IBA as we continue with this project.”